Home Tags Auristatin F hydroxypropylamide

Tag: auristatin F hydroxypropylamide

Mersana Therapeutics and Janssen Biotech Sign Agreement to Advance Novel Antibody-Drug...

ADC Review | Editorial Team
Mersana Therapeutics has signed a research collaboration and license agreement with Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to...
Gesso Italiano (Italian Chalk) in San Diego's Little Italy neighborhood celebrating its heritage by bringing the vibrancy and flavors of Italy to southern California. Courtesy: 2016 Fotolia.

Advanced Design of ADCs: Principles and Applications using Next Generation Linkers...

Rick Powers
Over the years there have been major challenges in the development of antibody-drug conjugates (ADC), including: choosing the right target, right antibody, right linker,...

Immunocapture-liquid Chromatography/Mass Spectrometry in Simultaneous Quantification of Total Antibody and ADC...

Peter Hofland
XMT-1522, an investigational antibody-drug conjugate (ADC) being developed by Mersana Therapeutics and Takeda, represents the first Dolaflexin®-based, cleavable ADC with a high drug-antibody ratio...

Mersana Presents Updated Data about its Dolasynthen Platform and Synthemer Scaffold

Peter Hofland
Clinical-stage bio-pharmaceutical company, Mersana Therapeutics, presented preclinical data from the company's proprietary Dolasynthen platform and its modular Synthemer scaffold during the 2019 Annual Meeting...
ADC Review, Journal of Antibody-drug Conjugates
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policymakers.

Latest

Peer Review

© 2013-2020 Sunvalley Communication, LLC. All Rights Reserved.

X